Portal de investigación
Role of antiangiogenic VEGF-A165b in angiogenesis and systolic function after reperfused myocardial infarction.
Fecha de publicación:
Fecha Ahead of Print:
Autores de INCLIVA
Grupos y Plataformas de I+D+i
Abstract
INTRODUCTION AND OBJECTIVES: Angiogenesis helps to reestablish microcirculation after myocardial infarction (MI). In this study, we aimed to further understand the role of the antiangiogenic isoform vascular endothelial growth factor (VEGF)-A165b after MI and to explore its potential as a coadjuvant therapy to coronary reperfusion.; METHODS: Two mice MI models were formed: a) permanent coronary ligation (nonreperfused MI); b) transient 45-minute coronary occlusion followed by reperfusion (reperfused MI); in both models, animals underwent echocardiography before euthanasia at day 21 after MI induction. We determined serum and myocardial VEGF-A165b levels. In both experimental MI models, we assessed the functional and structural role of VEGF-A165b blockade. In a cohort of 104 ST-segment elevation MI patients, circulating VEGF-A165b levels were correlated with cardiovascular magnetic resonance-derived left ventricular ejection fraction at 6 months and with the occurrence of adverse events (death, heart failure, and/or reinfarction).; RESULTS: In both models, circulating and myocardial VEGF-A165b levels were increased 21 days after MI induction. Serum VEGF-A165b levels inversely correlated with systolic function evaluated by echocardiography. VEGF-A165b blockade increased capillary density, reduced infarct size, and enhanced left ventricular function in reperfused, but not in nonreperfused, MI experiments. In patients, higher VEGF-A165b levels correlated with depressed ejection fraction and worse outcomes.; CONCLUSIONS: In experimental and clinical studies, higher serum VEGF-A165b levels are associated with worse systolic function. Their blockade enhances neoangiogenesis, reduces infarct size, and increases ejection fraction in reperfused, but not in nonreperfused, MI experiments. Therefore, VEGF-A165b neutralization represents a potential coadjuvant therapy to coronary reperfusion. Copyright © 2020 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
© 2020 Sociedad Española de Cardiología. Publicado por Elsevier España, S.L.U. Todos los derechos reservados
Datos de la publicación
- ISSN/ISSNe:
- 1885-5857, 1579-2242
- Tipo:
- Article
- Páginas:
- 131-139
- PubMed:
- 32474003
REVISTA ESPANOLA DE CARDIOLOGIA Elsevier Doyma
Citas Recibidas en Web of Science: 15
Documentos
Filiaciones
Financiación
Proyectos y Estudios Clínicos
A multidisciplinary project to advance in basic mechanisms, diagnosis, prediction, and prevention of cardiac damage in reperfused acute myocardial infarction.
Investigador Principal: VICENT BODÍ PERIS
PIE15/00013 . INSTITUTO SALUD CARLOS III . 2016
INCORPORACIÓN DE NUEVAS ÁREAS TEMÁTICAS Y NUEVOS GRUPOS AL CONSORCIO CIBER
Investigador Principal: JUAN SANCHIS FORES
CB16/11/00420 . INSTITUTO SALUD CARLOS III
Estudio multidisciplinar de la obstrucción microvascular y su reparación tras un infarto agudo de miocardio: de la arteria coronaria a la microcirculación. Foco en el factor VEGF-A165b (PI17/01836).
Investigador Principal: VICENT BODÍ PERIS
PI17/01836 . INSTITUTO SALUD CARLOS III . 2018
RETOS 2017. MODULACION FARMACOLOGICA DEL SISTEMA INMUNE COMO DIANA CLAVE EN LA PREVENCION DE LA ENFERMEDAD CARDIOVASCULAR ASOCIADA A DESORDENES METABOLICOS. SINTESIS DE FARMACOS NOVEDOSOS
Investigador Principal: MARIA JESUS SANZ FERRANDO
SAF2017-89714-R . MINISTERIO ECONOMIA Y COMPETITIVIDAD . 2018
Identificación de nuevos mecanismos implicados en la angiogénesis e inflamación en pacientes obesos. Modulación por ligandos de receptores nucleares constitutivos de androstano.
Investigador Principal: JOSE TOMAS REAL COLLADO
PI18/00209 . INSTITUTO SALUD CARLOS III . 2019
Un estudio multidisciplinar para avanzar en el entendimiento de los mecanismos básicos y la exploración de nuevas oportunidades terapéuticas en el infarto agudo de miocardio. Foco en los factores VEGF-A165b y ST2.
Investigador Principal: CÉSAR RIOS NAVARRO
FI18/00320 . INSTITUTO SALUD CARLOS III . 2019
CONTRATOS PREDOCTORALES DE FORMACIÓN EN INVESTIGACIÓN EN SALUD.
Investigador Principal: LUISA MARIA HUESO SOLER
FI19/00033 . INSTITUTO SALUD CARLOS III
Cita
Rios C,Hueso L,Diaz A,Marcos V,Bonanad C,Ruiz A,Vila JM,Sanz MJ,Chorro FJ,Piqueras L,Bodi V. Role of antiangiogenic VEGF-A165b in angiogenesis and systolic function after reperfused myocardial infarction. Rev. Esp. Cardiol. 2021. 74. (2):p. 131-139. IF:6,975. (1).
Role of antiangiogenic VEGF-A165b in angiogenesis and systolic function after reperfused myocardial infarction. Rios C, Hueso L, Diaz A, Marcos V, Bonanad C, Ruiz A, Vila JM et al. REVISTA ESPANOLA DE CARDIOLOGIA. 2021 febrero 01. 74 (2):131-139. DOI:10.1016/j.rec.2020.03.013. PMID:32474003.
